Taro Pharmaceutical Industries (NYSE:TARO) Upgraded to “B-” by TheStreet

Taro Pharmaceutical Industries (NYSE:TARO) was upgraded by equities researchers at TheStreet from a “c+” rating to a “b-” rating in a research note issued to investors on Monday, June 4th.

Other equities research analysts have also issued reports about the company. HC Wainwright initiated coverage on Taro Pharmaceutical Industries in a report on Monday, March 12th. They issued a “buy” rating and a $124.00 target price for the company. Zacks Investment Research upgraded Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a report on Saturday, May 26th. Finally, ValuEngine upgraded Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $129.50.

TARO traded down $0.11 on Monday, hitting $119.51. The company had a trading volume of 500 shares, compared to its average volume of 77,433. Taro Pharmaceutical Industries has a 1-year low of $93.01 and a 1-year high of $128.46. The firm has a market cap of $4.79 billion, a P/E ratio of 19.33 and a beta of 0.67.



Taro Pharmaceutical Industries (NYSE:TARO) last posted its earnings results on Thursday, May 17th. The company reported $2.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.51 by $0.66. Taro Pharmaceutical Industries had a return on equity of 11.33% and a net margin of 31.90%. The firm had revenue of $175.22 million during the quarter, compared to analyst estimates of $166.59 million. research analysts expect that Taro Pharmaceutical Industries will post 9.67 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP increased its position in Taro Pharmaceutical Industries by 8.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 260,672 shares of the company’s stock worth $25,739,000 after buying an additional 20,407 shares during the period. Fort L.P. increased its position in Taro Pharmaceutical Industries by 3.4% in the 1st quarter. Fort L.P. now owns 178,259 shares of the company’s stock worth $17,601,000 after buying an additional 5,848 shares during the period. Freestone Capital Holdings LLC increased its position in Taro Pharmaceutical Industries by 14.7% in the 1st quarter. Freestone Capital Holdings LLC now owns 166,748 shares of the company’s stock worth $16,464,000 after buying an additional 21,392 shares during the period. Arrowstreet Capital Limited Partnership bought a new position in Taro Pharmaceutical Industries in the 4th quarter worth approximately $11,093,000. Finally, Millennium Management LLC increased its position in Taro Pharmaceutical Industries by 2.7% in the 1st quarter. Millennium Management LLC now owns 104,861 shares of the company’s stock worth $10,354,000 after buying an additional 2,787 shares during the period. 10.67% of the stock is currently owned by institutional investors.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply